The regulatory landscape for AI-enabled medical devices, defined by the FDA, MHRA, and Health Canada, is often viewed as a series of hurdles. However, the documentation and technical rigor required for Good Machine Learning Practice (GMLP) and Predetermined Change Control Plans (PCCP) offer a unique opportunity for companies to identify and secure new Intellectual Property (IP) rights.

1. GMLP: A Roadmap for Method and Process Patents

GMLP encompasses 10 guiding principles focused on data quality, model integrity, and bias mitigation. To meet these standards, manufacturers must develop specific technical solutions that are often novel and non-obvious, making them eligible for patents.

• Innovating for Fairness: Regulators require “Fairness” and the mitigation of bias in training datasets. The unique algorithms or data-sampling techniques developed to ensure a model is representative of a target population can be patented as specific processes or methods.
• Methodological Transparency as Patent Enablement: The FDA’s demand for “methodological transparency”—including detailed descriptions of model architecture, features, and hyperparameters—essentially forces companies to create the high level of detail required for the written description and enablement standards of patent law (35 U.S.C. §112). By documenting these for regulators, companies simultaneously build the foundation for robust patent applications that are less vulnerable to invalidation.

2. PCCP: Securing the Future Evolution of the Device

A PCCP allows manufacturers to pre-specify future modifications to an AI model, such as performance improvements or adaptations to new data, without requiring a new regulatory submission for every change.

• Generating Rights on Iterative Improvements: The specific “Modification Protocols” and “Credibility Assessment Plans” within a PCCP often involve proprietary ways of monitoring real-world performance or integrating new data. These specific implementations can be protected as new layers of IP, ensuring that the device’s evolution is as legally protected as its initial version.
• Defining the Scope of Protection: Since a PCCP defines the boundaries of what is considered a “substantial modification,” it provides a technical roadmap that should be mirrored in a company’s patent portfolio strategy. This ensures that the exclusive rights granted by patents cover not only the current product but also the pre-authorized updates permitted by regulators.

3. Practice Tips for Leveraging Regulatory-Driven IP

• Patent the “Compliance Solution.” If you develop a unique software tool or architecture to meet a specific GMLP requirement (e.g., a new way to ensure data interpretability), file for a patent on that tool independently of the medical device itself.
• Sync PCCP with Patent Claims. Ensure that the technical modifications outlined in your PCCP are captured in your patent claims. This alignment prevents a competitor from “evolving” into your product’s space through their own iterative updates.
• Valuation through Dual Assets. Investors place a higher valuation on startups that can demonstrate both FDA clearance/PCCP status and granted patents, as this combination provides both the legal freedom to operate and the power to exclude competitors.

Conclusion

By viewing GMLP and PCCP not just as compliance tasks but as inventive processes, companies can systematically generate new IP. The detailed technical work required to satisfy regulators provides the perfect blueprint for a strong, defensible patent portfolio that protects the core “intelligence” of the medical device.